TrialClinical and vaccine immunology : CVI2016

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.

Mark S Riddle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.